Hosted on MSN23d
Medifast (NYSE:MED) Surprises With Q4 Sales But Quarterly Revenue Guidance Significantly Misses ExpectationsIs now the time to buy Medifast? Find out by accessing our full research report, it’s free. ・Revenue: $119 million vs analyst estimates of $114.3 million (37.7% year-on-year decline, ...
Is Medifast a buy or sell going into earnings? Read our full analysis here, it’s free. This quarter, analysts are expecting Medifast’s revenue to decline 40.2% year on year to $114.3 million ...
Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance. Insider trading is legal so long as the insiders report those trades to the ...
CEO Dan Chard highlighted that 2024 was a transformative year for Medifast due to the increasing adoption of GLP-1 weight loss medications. The company is adapting to these market shifts by ...
BALTIMORE (AP) — BALTIMORE (AP) — Medifast Inc. (MED) on Tuesday reported profit of $800,000 in its fourth quarter. On a per-share basis, the Baltimore-based company said it had profit of 7 cents.
Should You Invest in MEDIFAST INC (MED)? Before you invest in MEDIFAST INC (MED), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results